SEARCH:   Advanced

Blood, 15 October 2005, Vol. 106, No. 8, pp. 2723-2729. Prepublished online as a Blood First Edition Paper on June 21, 2005; DOI 10.1182/blood-2005-03-1290. This Article Full Text (PDF) All Versions of this Article: 2005-03-1290v1 106/8/2723    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Yee, D. L Articles by Bray, P. F Search for Related Content PubMed PubMed Citation Articles by Yee, D. L Articles by Bray, P. F Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 29, 2005 Accepted June 6, 2005 Aggregometry detects platelet hyperreactivity in healthy individuals Donald L Yee, Carol W Sun, Angela L Bergeron, Jing-fei Dong, and Paul F Bray* Department of Pediatrics, Hematology-Oncology Section, Baylor College of Medicine, Houston, TX, USA Department of Medicine, Thrombosis Research Section, Baylor College of Medicine, Houston, TX, USA Department of Pediatrics, Hematology-Oncology Section, Baylor College of Medicine, Houston, TX, USA; Department of Medicine, Thrombosis Research Section, Baylor College of Medicine, Houston, TX, USA * Corresponding author; email: pbray{at}bcm.tmc.edu. Aggregometry is widely used to assess platelet function, but its utility in identifying platelet hyperreactivity is poorly defined. We studied platelet aggregation in 359 healthy individuals using the agonists ADP, epinephrine, collagen, collagen-related peptide and ristocetin. We also assessed the reproducibility of these assays in 27 subjects by studying them repeatedly on at least four separate occasions. Healthy subjects exhibited considerable inter-individual variability in aggregation response to agonists, especially at concentrations lower than those typically used in clinical laboratories. For each agonist tested at these submaximal concentrations, a small proportion of individuals demonstrated an unusually robust aggregation response. Subjects who exhibited such in vitro hyperreactivity to one agonist tended to demonstrate a similar response to others, suggesting that hyperreactivity is a global characteristic of platelets. Epinephrine and collagen-related peptide were especially reliable and efficient in detecting hyperreactivity. For epinephrine, excellent reproducibility persisted for up to three years, and hyperreactivity was associated with female gender and higher fibrinogen levels (p< .02). We recommend these assays as appropriate candidates for future studies requiring accurate assessment of increased platelet reactivity. These include clinical studies to improve risk assessment for arterial thrombosis, as well as genetic studies to establish determinants of the hyperreactive platelet phenotype. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. I. Jones, S. Bray, S. F. Garner, J. Stephens, B. de Bono, W. G. J. Angenent, D. Bentley, P. Burns, A. Coffey, P. Deloukas, et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways Blood, August 13, 2009; 114(7): 1405 - 1416. [Abstract] [Full Text] [PDF] T Geisler, M Kapp, K Gohring-Frischholz, K Daub, C Dosch, B Bigalke, H Langer, C Herdeg, and M Gawaz Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease Heart, June 1, 2008; 94(6): 743 - 747. [Abstract] [Full Text] [PDF] Z. Pamuklar, J. S. Lee, H.-Y. Cheng, M. Panchatcharam, S. Steinhubl, A. J. Morris, R. Charnigo, and S. S. Smyth Individual Heterogeneity in Platelet Response to Lysophosphatidic Acid: Evidence for a Novel Inhibitory Pathway Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): 555 - 561. [Abstract] [Full Text] [PDF] P. A. Gurbel, R. C. Becker, K. G. Mann, S. R. Steinhubl, and A. D. Michelson Platelet Function Monitoring in Patients With Coronary Artery Disease J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1822 - 1834. [Abstract] [Full Text] [PDF] D. I. Simon and A. H. Schmaier Sweet and Sticky: Diabetic Platelets, Enhanced Reactivity, and Cardiovascular Risk J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1548 - 1550. [Full Text] [PDF] D. J. Angiolillo, E. Bernardo, M. Sabate, P. Jimenez-Quevedo, M. A. Costa, J. Palazuelos, R. Hernandez-Antolin, R. Moreno, J. Escaned, F. Alfonso, et al. Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1541 - 1547. [Abstract] [Full Text] [PDF] J. E. Freedman Heritability, Platelet Function, and Aspirin: A Link Established but Cause Unknown Circulation, May 15, 2007; 115(19): 2468 - 2470. [Full Text] [PDF] B. T. Ivandic, E. Giannitsis, P. Schlick, P. Staritz, H. A. Katus, and T. Hohlfeld Determination of Aspirin Responsiveness by Use of Whole Blood Platelet Aggregometry Clin. Chem., April 1, 2007; 53(4): 614 - 619. [Abstract] [Full Text] [PDF] T. H. Wang, D. L. Bhatt, and E. J. Topol Aspirin and clopidogrel resistance: an emerging clinical entity Eur. Heart J., March 2, 2006; 27(6): 647 - 654. [Abstract] [Full Text] [PDF] B. T. Ivandic, P. Schlick, P. Staritz, K. Kurz, H. A. Katus, and E. Giannitsis Determination of Clopidogrel Resistance by Whole Blood Platelet Aggregometry and Inhibitors of the P2Y12 Receptor Clin. Chem., March 1, 2006; 52(3): 383 - 388. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020